Corporate
Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth
Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments
Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans
Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery
Starboard Value Criticizes Pfizer Leadership Over Underperforming R&D and Overpriced Acquisitions
Pfizer Inc., Starboard Value, Activist Investor, Pharmaceutical Industry, R&D Underperformance, Overpaid M&A Deals, Corporate Accountability
Pfizer’s Former Executives Back Activist Investor Starboard’s Revamp Plan
Pfizer, Starboard Value, activist investor, Ian Read, Frank D’Amelio, Albert Bourla, pharmaceutical industry, corporate governance
BioMarin Undergoes Strategic Restructuring Amid Slow Roctavian Sales and Staff Layoffs
BioMarin, restructuring, Roctavian, staff layoffs, corporate strategy, hemophilia gene therapy
Galapagos Investor Seeks to Influence Company Control, Citing Undervaluation
Galapagos, investor influence, undervaluation, biotech, corporate control
Sen. Wyden Scrutinizes Pfizer’s Tax Rate Amidst Ongoing Investigation
Sen. Wyden, Pfizer, tax rate, investigation, corporate taxation, tax avoidance, pharmaceutical industry, financial transparency
Novartis Appoints Ex-Bristol Myers CEO Giovanni Caforio as Chair: Potential for Future M&A Deals?
Novartis, Bristol Myers, Giovanni Caforio, Chair, Mergers and Acquisitions (M&A), Pharmaceutical Industry, Corporate Strategy, Leadership Change.
Novartis Announces 680 Layoffs in Development Group Amid Corporate Restructuring
Novartis, Layoffs, Development Group, Corporate Restructuring, 680 Jobs, Switzerland, United States, Pharmaceutical Industry